Teladoc Health, Inc. (TDOC) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Teladoc Health’s revenue went from $123M in fiscal 2016 to $2.5B in fiscal 2025, growth of about 39.9% a year.
Net income in fiscal 2025 was -$200M, a net margin of -7.9%; the best year in this period was 2016 with -$74M.
Over the twelve months to September 30, 2026, revenue was $2.5B and net income -$155M.
Free cash flow was $285M in fiscal 2025 and positive in 6 of the 10 years shown.
The diluted share count rose 316% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.5B | $2.5B | $2.6B | $2.6B | $2.4B | $2.0B | $1.1B | $553M | $418M | $233M | $123M |
| Gross profit | — | — | — | — | $1.7B | $1.4B | $703M | $369M | $289M | $172M | $91M |
| Operating income | -$163M | -$263M | -$1.0B | -$249M | -$13.7B | -$266M | -$506M | -$80M | -$71M | -$75M | -$63M |
| Net income | -$155M | -$200M | -$1.0B | -$220M | -$13.7B | -$429M | -$485M | -$99M | -$97M | -$107M | -$74M |
| EPS (diluted) | $-0.86 | $-1.14 | $-5.87 | $-1.34 | $-84.60 | $-2.73 | $-5.36 | $-1.38 | $-1.47 | $-1.93 | $-1.75 |
| R&D | $268M | $278M | $307M | $349M | $334M | $312M | $165M | $65M | $54M | $34M | $22M |
| Revenue growth | — | −1.5% | −1.3% | +8.1% | +18.4% | +85.8% | +97.7% | +32.4% | +79.1% | +89.4% | +59.2% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $268M | $294M | $294M | $350M | $189M | $194M | -$54M | $30M | -$5M | -$34M | -$52M |
| Capital spending | -$6M | -$9M | -$11M | -$11M | -$16M | -$9M | -$4M | -$4M | -$4M | -$3M | -$2M |
| Free cash flow | $262M | $285M | $283M | $339M | $173M | $185M | -$58M | $26M | -$9M | -$37M | -$54M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based pay | $51M | $80M | $146M | $202M | $218M | $303M | $476M | $67M | $44M | $31M | $8M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $781M | $1.3B | $1.1B | $918M | $896M | $787M | $517M | $479M | $43M | $50M |
| Debt | — | $1.0B | $1.0B | $1.6B | $1.6B | $1.3B | $1.5B | $470M | $415M | $207M | $44M |
| Equity | — | $1.4B | $1.5B | $2.3B | $2.3B | $16.0B | $15.9B | $1.0B | $1.0B | $559M | $231M |
| Total assets | — | $2.9B | $3.5B | $4.4B | $4.3B | $17.7B | $17.8B | $1.6B | $1.5B | $824M | $304M |
| Shares (diluted) | 182M | 176M | 171M | 165M | 161M | 157M | 91M | 72M | 66M | 55M | 42M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | — | — | — | 69.1% | 68.0% | 64.3% | 66.7% | 69.2% | 73.6% | 74.0% |
| Operating margin | -6.6% | -10.4% | -39.7% | -9.6% | -567.3% | -13.1% | -46.3% | -14.5% | -17.0% | -32.3% | -50.9% |
| Net margin | -6.3% | -7.9% | -39.0% | -8.5% | -567.5% | -21.1% | -44.4% | -17.9% | -23.2% | -45.8% | -60.3% |
| FCF margin | 10.6% | 11.3% | 11.0% | 13.0% | 7.2% | 9.1% | -5.3% | 4.8% | -2.1% | -15.9% | -43.8% |
| ROIC | — | -9.2% | -31.9% | -5.0% | -350.5% | -1.2% | -2.5% | -4.9% | -3.9% | -9.8% | -18.0% |
| ROE | — | -14.5% | -67.2% | -9.5% | -591.9% | -2.7% | -3.0% | -9.8% | -9.6% | -19.1% | -32.1% |
Frequently asked questions
What is Teladoc Health’s annual revenue?
$2.5B in fiscal 2025 and $2.5B over the twelve months to September 30, 2026.
How much profit does Teladoc Health make?
Net income was -$200M in fiscal 2025 (net margin -7.9%).
Is Teladoc Health’s revenue growing?
No: revenue fell 1.5% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.